BRÈVE

sur ACTICOR BIOTECH (isin : FR0014005OJ5)

Acticor Biotech Advances Glenzocimab in Myocardial Infarction Treatment

Acticor Biotech is progressing with the development of glenzocimab, a drug aimed at addressing cardiovascular emergencies, with a focus on myocardial infarction, particularly ST-Elevation Myocardial Infarction (STEMI). The company reports that 27 patients have been recruited for the phase 2b LIBERATE study, which aims to evaluate glenzocimab's efficacy in reducing the size of myocardial infarctions and minimizing microvascular complications. This study is a partnership with the University of Birmingham, UK, and results are anticipated by Q4 2026.

Additionally, a phase 2 study named GLORIA is being prepared. It will assess glenzocimab's efficiency in angioplasty and aims to enroll 300 STEMI patients. The study will explore various dosages and optimize the drug's administration mode. Recruitment could begin in Q1 2025, contingent upon funding.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de ACTICOR BIOTECH